TP53 and intrahepatic cholangiocarcinoma: The increase from 65% based on WHO 2017 to 69% following ICC was mainly mediated by introducing the new entity AML with mutated TP53 comprising 52 cases of which the majority was former AML-MRC (48/52; 92%).